ATE437653T1 - Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika - Google Patents
Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotikaInfo
- Publication number
- ATE437653T1 ATE437653T1 AT04753672T AT04753672T ATE437653T1 AT E437653 T1 ATE437653 T1 AT E437653T1 AT 04753672 T AT04753672 T AT 04753672T AT 04753672 T AT04753672 T AT 04753672T AT E437653 T1 ATE437653 T1 AT E437653T1
- Authority
- AT
- Austria
- Prior art keywords
- dose
- antimitotics
- combination
- treated
- antimitotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47490603P | 2003-05-30 | 2003-05-30 | |
US10/856,742 US7691838B2 (en) | 2003-05-30 | 2004-05-27 | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
PCT/US2004/016888 WO2005000314A1 (en) | 2003-05-30 | 2004-05-28 | Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE437653T1 true ATE437653T1 (de) | 2009-08-15 |
Family
ID=33555375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04753672T ATE437653T1 (de) | 2003-05-30 | 2004-05-28 | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika |
Country Status (6)
Country | Link |
---|---|
US (1) | US7691838B2 (de) |
EP (1) | EP1628667B1 (de) |
AT (1) | ATE437653T1 (de) |
DE (1) | DE602004022285D1 (de) |
ES (1) | ES2329134T3 (de) |
WO (1) | WO2005000314A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
US20090197852A9 (en) * | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
WO2004089304A2 (en) * | 2003-04-01 | 2004-10-21 | Hollis-Eden Pharmaceuticals, Inc. | Antiandrogens with marginal agonist activity and methods of use |
US20050020534A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
US20050026893A1 (en) * | 2003-05-30 | 2005-02-03 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
US20050020556A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
EP2298748B1 (de) | 2004-11-18 | 2016-07-20 | Synta Pharmaceuticals Corp. | HSP90-Aktivität modulierende Triazolverbindungen |
DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
JP4956737B2 (ja) * | 2005-02-23 | 2012-06-20 | 国立大学法人名古屋大学 | 抗ポリグルタミン病剤 |
TWI446910B (zh) | 2005-08-18 | 2014-08-01 | Synta Pharmaceuticals Corp | 調節hsp90活性的***化合物 |
US20090062222A1 (en) * | 2005-09-29 | 2009-03-05 | Trustees Of Boston University | Methods for Sensitizing Cancer Cells to Inhibitors |
US7648976B2 (en) * | 2005-11-23 | 2010-01-19 | Bristol-Myers Squibb Company | 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
US20090042847A1 (en) * | 2005-11-23 | 2009-02-12 | Kosan Biosciences Incorporated | 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
AU2007267852A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate Hsp90 activity and methods for identifying same |
DE102007002715A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
EP2560640A1 (de) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer |
CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法 |
JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とhsp90阻害剤の組合せ療法 |
JP2014533299A (ja) | 2011-11-14 | 2014-12-11 | シンタ ファーマシューティカルズ コーポレーション | Braf阻害剤とhsp90阻害剤の組合せ療法 |
WO2015036643A2 (es) * | 2013-09-13 | 2015-03-19 | Sierra Jiménez Angels | Marcador para predecir metástasis del cancer de mama |
KR20160015076A (ko) | 2014-07-30 | 2016-02-12 | 삼성전자주식회사 | c-Met 저해제의 효능 예측을 위한 바이오마커 Hsp90 |
CN105497034B (zh) * | 2015-12-08 | 2018-08-07 | 暨南大学 | 一种通过靶向prmt5抑制骨肉瘤生长的组合物及其制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
AU3922193A (en) * | 1992-03-23 | 1993-10-21 | Georgetown University | Liposome encapsulated taxol and a method of using the same |
US5387584A (en) * | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
WO1994026254A1 (en) * | 1993-05-17 | 1994-11-24 | The Liposome Company, Inc. | Incorporation of taxol into liposomes and gels |
US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5932566A (en) | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
DK0932399T3 (da) | 1996-03-12 | 2006-05-15 | Pg Txl Co Lp | Vandoplöselige paclitaxel-prodrugs |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
DE19744676A1 (de) | 1997-10-10 | 1999-04-15 | Forschungszentrum Borstel Zent | Kombinationspräparate für die Therapie von Tumoren |
US6682758B1 (en) | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
US6245759B1 (en) * | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6174875B1 (en) * | 1999-04-01 | 2001-01-16 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
KR20070058028A (ko) | 1999-05-24 | 2007-06-07 | 소너스파머슈티칼즈인코포레이티드 | 난용성 약물용 에멀젼 부형제 |
GB9918429D0 (en) | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
ES2234698T3 (es) * | 1999-10-19 | 2005-07-01 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
US6313138B1 (en) * | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
EP1322307B1 (de) | 2000-07-28 | 2011-09-28 | Sloan-Kettering Institute For Cancer Research | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen |
JPWO2002015925A1 (ja) | 2000-08-22 | 2004-07-08 | 協和醗酵工業株式会社 | アポトーシスの制御方法およびアポトーシス制御ポリペプチド |
WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
US7211562B2 (en) * | 2000-11-02 | 2007-05-01 | Sloan-Kettering Institute For Cancer Research | Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors |
WO2002079167A1 (en) * | 2001-03-30 | 2002-10-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Geldanamycin derivative and method of treating cancer using same |
US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
EP2336133A1 (de) | 2001-10-30 | 2011-06-22 | Conforma Therapeutics Corporation | Purinanaloga mit HSP90-inhibierender Wirkung |
WO2003041643A2 (en) * | 2001-11-09 | 2003-05-22 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
WO2003050295A2 (en) | 2001-12-12 | 2003-06-19 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating hsp90 binding activity |
GB0207362D0 (en) | 2002-03-28 | 2002-05-08 | Univ Liverpool | Chemotherapy |
EP1492522A4 (de) | 2002-04-10 | 2009-01-14 | Conforma Therapeutics Corp | Ansamycin-formulierungen und verfahren zu ihrer herstellung und verwendung |
EP1581261A4 (de) | 2002-12-12 | 2009-10-21 | Conforma Therapeutics Corp | Zytotoxine und mittel für diagnostische bildgebung mit hsp90-liganden |
ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
-
2004
- 2004-05-27 US US10/856,742 patent/US7691838B2/en not_active Expired - Fee Related
- 2004-05-28 WO PCT/US2004/016888 patent/WO2005000314A1/en active Application Filing
- 2004-05-28 ES ES04753672T patent/ES2329134T3/es not_active Expired - Lifetime
- 2004-05-28 EP EP04753672A patent/EP1628667B1/de not_active Expired - Lifetime
- 2004-05-28 DE DE602004022285T patent/DE602004022285D1/de not_active Expired - Lifetime
- 2004-05-28 AT AT04753672T patent/ATE437653T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE602004022285D1 (de) | 2009-09-10 |
US20050020558A1 (en) | 2005-01-27 |
EP1628667A4 (de) | 2007-04-04 |
ES2329134T3 (es) | 2009-11-23 |
US7691838B2 (en) | 2010-04-06 |
EP1628667A1 (de) | 2006-03-01 |
EP1628667B1 (de) | 2009-07-29 |
WO2005000314A1 (en) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE437653T1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
ATE382346T1 (de) | Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten | |
WO2005000213A3 (en) | Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors | |
WO2005000211A3 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes | |
WO2005000212A8 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors | |
NO20050450L (no) | Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft | |
MY151032A (en) | Treatment of tnf? related disorders | |
DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
WO2004108080A3 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with immunosuppressants | |
TW200507833A (en) | Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents | |
WO2004030625A3 (en) | Synergistic methods and compositions for treating cancer | |
DE69924641D1 (de) | Behandlung von asthma anhand von mek-inhibitoren | |
DE60312516D1 (de) | Inhibitoren von mitotischem kinesin | |
ATE250932T1 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
WO2005000214A3 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics | |
MY138732A (en) | Conjugated complement cascade inhibitors | |
ATE495735T1 (de) | Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden | |
ATE411018T1 (de) | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) | |
WO2004091540A3 (en) | Methods of treating pain and compositions for use therefor | |
ATE430572T1 (de) | Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie | |
MX2024000986A (es) | Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus. | |
EA200501166A1 (ru) | Составы и способы лечения тромбоцитемии | |
DE60231896D1 (de) | Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus | |
DE602004016126D1 (de) | Aplidine zur behandlung von multiplem myelom | |
ATE338566T1 (de) | Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |